Voyager Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
06/08/2025 21:38
Voyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 57 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of twelve analysts for the quarter was for a loss of 53 cents per share. Wall Street expected results to range from -80 cents to -31 cents per share. Revenue fell 82.4% to $5.20 million from a year ago; analysts expected $9.91 million. Voyager Therapeutics Inc's reported EPS for the quarter was a loss of 57 cents. The company reported a quarterly loss of $33.38 million. Voyager Therapeutics Inc shares had risen by 8.7% this quarter and lost 40.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Voyager Therapeutics Inc is $15.00, about 77.5% above its last closing price of $3.38 This summary was machine generated from LSEG data August 6 at 08:37 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.53 | -0.57 | Missed |
| Mar. 31 2025 | -0.45 | -0.53 | Missed |
| Dec. 31 2024 | -0.37 | -0.59 | Missed |
| Sep. 30 2024 | -0.45 | -0.16 | Beat |
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview